Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Ascendis Pharma A/S — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.51 (market cap $2.14B), while Ascendis Pharma A/S trades at $257.91 (market cap $16.67B). The key difference: Ascendis Pharma A/S is far larger — about 7.8× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| AMC | ASND | |
|---|---|---|
Market Cap | $2.14B | $16.67B |
Sector | Media | Health |
52-Week High | $3.15 | $277.18 |
52-Week Low | $0.95 | $189.74 |
Enterprise Value | $9.08B | $17.04B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $2.465, up 1.86% on the day, with a bullish technical signal and recent earnings beats. The company reported record revenue and EBITDA in Q2 2026, with improving cash flow trends. However, it remains unprofitable with a net income margin of -10.59% and negative shareholder equity of -$1.76 billion. Analyst consensus is mixed with a $3.00 price target.
Outlook hinges on sustained box office recovery and cost discipline to achieve profitability. Key risks include high debt load, competitive pressures, and reliance on blockbuster films. Upside potential exists if operational improvements continue, but financial stability remains a concern for investors.
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
